Events
Past presentations
  • Panel session: “The state of Alzheimer’s disease in Europe - innovation, value and challenges for HTA”. J. Bouvy, J. Georges, R. Handels, M. Knapp & C. Reed, Health Technology Assessment international (HTAi) Annual Meeting,17-21 June 2017, Rome (Italy).
  • Poster presentation: "Overcoming ethical issues in sharing real-world evidence in Alzheimer’s disease: The ROADMAP Project”. J. Krutzinna, Neuroethics Network 2017, 19-21 June 2017, Paris (France).
  • Poster presentation: “Real World Evidence for Alzheimer’s disease Outcomes”, Alzheimer's Association International Conference (AAIC), 16-20 July 2017, London (UK).
  • Oral presentation: “Actualités sur l’Aducanumab et étude ROADMAP”. Journées scientifiques de la fédération nationale des Centres Mémoire Ressources Recherche (FCMRR), 28-29 September 2017, Montpellier (France).
  • Symposium: “Engaging with patient organizations within IMI consortia to inform quality, relevance and value in Alzheimer’s research – insights from MOPEAD, EPAD and ROADMAP”. As part of Lilly symposium, Alzheimer Europe Conference, 2-4 October 2017, Berlin (Germany).
  • Poster presentation: “Challenges in Optimising Real World Evidence for Alzheimer’s Disease”. C. Reed, F. de Reydet de Vulpillieres, J. Gallacher, Clinical Trials on Alzheimer’s Disease (CTAD 2017), 1-4 November 2017, Boston, MA (USA).
  • Oral presentation: “Challenges in Optimizing Real World Evidence for Alzheimer’s Disease”. C. Reed, F. de Reydet de Vulpillieres, J. Gallacher, International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress, 4-8 November 2017, Glasgow (UK). http://www.sciencedirect.com/science/article/pii/S1098301517303716
  • Poster presentation: "A model for Alzheimer’s disease in the prevention setting". N. Hummel, et al., International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress 2017, 4-8 November 2017, Glasgow (UK).
  • Oral presentation: "The aims of the ROADMAP project". C. Reed, Alzheimer Association Academy, 5-6 December 2017, Brussels (Belgium).
  • Oral presentation: "The use of real-world data and evidence in regulatory and health technology assessments". M. Dekker, Alzheimer Association Academy, 5-6 December 2017, Brussels (Belgium).
  • Oral presentation: "Ethical issues raised by big data and real-world evidence projects". A. Turner, Alzheimer Association Academy, 5-6 December 2017, Brussels (Belgium).
  • Oral presentation: "Expert advisory involvement in ROADMAP". A. Santuccione Chadha, Closed meeting at Lausanne IV, 13 December 2017, Lausanne (Switzerland).
  • Poster presentation: “Real World Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform”. O. Janssen, S. Vos, R. Handels, F. Verhey, P. J. Vissser,  Symposium: The Future of a Data-Driven Society, 25 January 2018, Maastricht (the Netherlands).
  • Oral presentation: “Real-world evidence in Alzheimer’s disease: the ROADMAP collaboration”. P. J. Visser, International Pharmaco-Economic Conference on Alzheimer's Disease (IPECAD), 15-16 February 2018, Paris (France).
  • Oral presentation: "Data sharing in biomedical research: practical questions". C. Diaz, XI Annual Conference of Technological Platforms in Biomedical Research, 5 March 2018, Barcelona (Spain).
  • Oral presentation: "Real world evidence for investigating AD outcomes: utilising platform resources". N. Vaci, IMI-EMIF Symposium ‘Liberating Evidence from European Health Data – the Achievements and Challenges of a Five-Year IMI Project’, 18 April 2018, Brussels (Belgium).
  • Poster presentation: "Predictive modelling for secondary prevention of Alzheimer's disease: Ethical concerns and social implications based on targeted, narrative literature review". Z. Angehrn, et al., International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting, 19-23 May 2018, Baltimore MD (USA).
  • Forum presentation: "Using real-world data to replace missing data for regulatory submissions". H. Kracher, International Society For Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting, 21 May 2018, Baltimore MD (USA).
  • Oral presentation: “Regulatory and HTA considerations in Alzheimer’s disease”. J. Bouvy, HTAi 2018 Meeting, 5 June 2018, Vancouver (Canada).
  • Roundtable discussion: “Real world data and dementia: contributions from the Information System for the development of primary care research (SIDIAP) and the Girona Dementia Register (ReDeGi)”. A. Ponjoan, 11th Research Day of the IDIAPJGol and the 10th Research Day of Catalan Health Institute (ICS), 7 June, Barcelona (Spain).
  • Oral presentation: “Neuroethics in Dementia Prevention and Treatment: Early intervention for better life long brain health. Findings from the ROADMAP project”. A. McKeown, 5th Institute of Medical Ethics Summer Conference, 19-20 June, Oxford (UK).
  • Oral presentation: "Health-related quality of life in people with dementia measured with preference based instruments: a systematic literature review and meta-analysis". F. Landeiro, et al., XXXVIII Jornadas de Economía de Salud, 21 June 2018, Las Palmas (Spain).
  • Two of our ROADMAP teams (Outcome Definition and ELSI) met with the members of the European Working Group of People With Dementia for an interactive feedback session, presenting, discussing and refining conclusions from their consultations in two separate sessions, on 27 June 2018, Brussels (Belgium).
  • Oral presentation as part of "Women and Dementia” parallel session: "Female caregivers’ perspectives on the most important outcomes of Alzheimer’s disease and dementia". C. Tochel, Alzheimer's Disease International Conference, 27 July 2018, Chicago (USA).
  • Oral presentation: “Neuroethics in dementia prevention”. A. McKeown, 32nd European Conference on philosophy of medicine and health care, 24 August 2018, Lisbon (Portugal).
  • Poster presentation: "The value of an Expert Advisory Group: Exploration of barriers and facilitators within the ROADMAP international big data project". D. O'Rourke, et al., Guidelines International Network, 12-14 September 2018, Manchester (UK).
  • Poster presentation: "Identifying priority outcomes and understanding meaningful delay in disease progression for Alzheimer’s Disease across the spectrum". A. Ly, IMI 10th anniversary scientific symposium, 22-23 October 2018, Brussels (Belgium).
  • Poster presentation: "Alignment of European regulatory and health technology assessments: a review of licensed products for Alzheimer’s disease". M. Dekker, IMI 10th anniversary scientific symposium, 22-23 October 2018, Brussels (Belgium).
  • Poster presentation: "Regulatory and HTA considerations for disease-modifying drugs in Alzheimer's disease". D. O'Rourke, IMI 10th anniversary scientific symposium, 22-23 October 2018, Brussels (Belgium).
  • Closed session at the Clinical Trials on Alzheimer's Disease (CTAD) conference, 26 October 2018, Barcelona (Spain) . Read the conference brochure here.
  • Pleanary talk and four parallel sessions: "Real-world evidence in Alzheimer's disease". 28th Alzheimer Europe Conference, 29-31 October 2018, Barcelona (Spain). Read the conference brochure here.
  • Oral Presentation: “Neuroethics in dementia prevention: ethical issues in early intervention for better life long brain health – findings from the ROADMAP project”. A. McKeown, 2018 International Neuroscience Society Annual Meeting, 1-2 November 2018, San Diego, CA (USA).